INDIVIDUAL TEST 868
KCNA2 antibodies (IgG)
Indication
Suspected Autoimmune encephalitis or atypical dementia.
Method
Cell-based assay (CBA), indirect immunofluorescence. The method is not yet validated for clinical diagnostic use.
Result
Results are reported as negative or positive. A positive result is followed by a titer (serum). Can be tested in serum and CSF.
Reference interval (serum): <1:10 negative
Reference interval (CSF): negative
Interpretation
Autoantibodies against the potassium voltage-gated channel subfamily A 2 subunit (KCNA2), have been found in patients suffering from cognitive impairment, memory disturbance and neuropsychiatric symptoms. Epileptic seizures, gait disorder, and ataxia have also been described.
Patients positive for antibodies against KCNA2 in CSF are more likely to suffer from cognitive impairment compared to seropositive patients.
References
Arlt FA et al. KCNA2 IgG autoimmunity in neuropsychiatric diseases. Brain Behav Immun. 2024 Mar;117:399-411. doi: 10.1016/j.bbi.2024.01.220. Epub 2024 Feb 2. PMID: 38309639.
Timäus C, von Gottberg P, Hirschel S, Lange C, Wiltfang J, Hansen N. KCNA2 Autoimmunity in Progressive Cognitive Impairment: Case Series and Literature Review. Brain Sci. 2021 Jan 12;11(1):89. doi: 10.3390/brainsci11010089. PMID: 33445475; PMCID: PMC7826663.
Can't find what you're looking for? We are here to help
ENSKILD ANALYS 868
KCNA2 antikroppar (IgG)
Indikation
Misstanke om autoimmun encefalit eller atypisk demens.
Metod
Cell-based assay (CBA), indirekt immunofluorescens. Metoden är ännu inte validerad för klinisk diagnostik.
Resultat
Resultat anges som negativt eller positivt. Positivt resultat titreras (serum). Kan testas i serum och likvor.
Referensintervall (serum): <1:10 negativt
Referensintervall (likvor): negativt
Tolkning
Antikroppar mot kaliumkanalens subenhet A 2 (KCNA2) har rapporterats förekomma vid kognitiv påverkan med minnesrubbning och neuropsykiatriska symptom. Även fall med epilepsi, gångstörning och ataxi har rapporterats.
Förekomst av antikroppar mot KCNA2 i likvor är starkare associerat med kognitiv påverkan än seropositivitet.
Referenser
Arlt FA et al. KCNA2 IgG autoimmunity in neuropsychiatric diseases. Brain Behav Immun. 2024 Mar;117:399-411. doi: 10.1016/j.bbi.2024.01.220. Epub 2024 Feb 2. PMID: 38309639.
Timäus C, von Gottberg P, Hirschel S, Lange C, Wiltfang J, Hansen N. KCNA2 Autoimmunity in Progressive Cognitive Impairment: Case Series and Literature Review. Brain Sci. 2021 Jan 12;11(1):89. doi: 10.3390/brainsci11010089. PMID: 33445475; PMCID: PMC7826663.